<DOC>
	<DOCNO>NCT02537171</DOCNO>
	<brief_summary>The study evaluate efficacy Apatinib patient advance metastatic adenocarcinoma stomach gastroesophageal junction .</brief_summary>
	<brief_title>Apatinib Maintenance Therapy After First Line Treatment Locally Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>The study investigate efficacy Apatinib maintenance therapy first fine treatment patient advance metastatic adenocarcinoma stomach gastroesophageal junction progression-free survival ( PFS ) . Apatinib give patient receive first-line chemotherapy efficacy assessment stable disease ( SD ) , complete response ( CR ) , partial response ( PR ) 4 cycle . Patients randomly assign 750mg group 500mg group continually disease progression intolerable toxicity patient withdrawal consent , sample size 40 individual .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age≥18 year ; 2 . Pathologically diagnose advanced gastric adenocarcinoma ( include gastroesophageal junction ) measurable metastasis outside stomach ( ≥10mm spiral CT scan , meet criterion Response Evaluation Criteria Solid Tumors 1.1 ) ; 3 . Locally advanced , recurrent metastatic gastric gastrooesophageal junction adenocarcinoma ; 4 . Finished firstline chemotherapy ( fluorouracil combine oxaliplatin , cisplatin , paclitaxel docetaxel ) 3 week cycle 4 cycle , last efficacy assessment SD , PR CR . No 28 day start day last cycle chemotherapy ; 5 . Eastern Cooperative Oncology Group（ECOG）performance status 0 1 ; 6 . Blood routine test Biochemical test : Hemoglobin ≥ 80g / L ; Absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ; Platelet count≥ 90 × 109 / L ; Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; 2.5× upper limit normal ( ULN ) ; liver metastasis , , ALT AST &lt; 5 × ULN ; Serum total bilirubin≤1.5 × ULN ; Serum creatinine≤1.5 × ULN ; Serum albumin≥30g/L ; 7 . Life expectancy 3 month ; 8 . Voluntarily join study sign Informed Consent Form study ; 9 . Pregnancy test ( serum urine ) perform woman childbearing age within 7 day enrolment test result must negative . They shall take appropriate method contraception study 8th week post last administration study drug . For men , ( previous surgical sterilization accept ) , shall agree take appropriate method contraception study 8th week post last administration study drug . 1 . Patients known history allergic reaction and/or hypersensitivity attribute apatinib accessory ; 2 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; Coronary heart disease great ClassⅠ ; Ⅰlevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class Ⅰcardiac dysfunction ; Patients positive urinary protein ; 3 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 4 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , haematemesis past 2 month ; primary lesion stomach positive fecal occult blood test ( + ) evaluate endoscopy potential massive haemorrhage condition evaluate investigator ; 5 . Abnormal Coagulation ( international normalize ratio &gt; 1.5 , activate partial thromboplastin time &gt; 1.5 UNL ) , tendency bleeding ; 6 . Associated central nervous system ( CNS ) metastases ; 7 . Pregnant lactating woman ; 8 . Suffering malignancy within 5 year ; 9 . History uncontrolled psychotropic drug abuse mental disorder ; 10 . Participated clinical study within 4 week ; 11 . Prior VEGFR inhibitor treatment , sorafenib sunitinib ; 12 . Concomitant disease condition judge investigator may seriously affect subject 's safety affect study completion ; 13 . Other case researcher find ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>Locally Advanced Gastric Cancer</keyword>
	<keyword>Metastatic Gastric Cancer</keyword>
</DOC>